1. T-Cell Directed Therapy in MS

3. Program Objectives

4. T Cells and B Cells in MS

5. T-Cell Directed Therapies: Alemtuzumab and Cladribine

6. T-Cell Directed Therapies: Daclizumab

7. T-Cell Directed Therapies: Fingolimod

8. T-Cell Directed Therapies: Natalizumab

9. T-Cell Directed Therapies: DMF

10. Evolution of Outcome Measures in MS

11. Evolution of NEDA in MS[a]

12. Practical Considerations in Implementing NEDA in Clinical Practice

13. NEDA as an Endpoint: Single-Center Data

14. NEDA as an Endpoint: Single-Center Data (cont)

15. NEDA as an Endpoint: Clinical Trial Data

16. Achieving NEDA With Cladribine: CLARITY

17. Achieving NEDA With Alemtuzumab: CARE-MS

18. Achieving NEDA With Daclizumab: DECIDE

19. Achieving DAF With Natalizumab: AFFIRM

20. Achieving NEDA With DMF: DEFINE/CONFIRM

21. Achieving NEDA-3 and NEDA-4 With Fingolimod: TRANSFORMS

22. Challenge of Implementing NEDA-4 in Clinical Practice

23. Achieving NEDA With Fingolimod: Real-World Data

24. Benefit/Risk Assessment in Targeting NEDA

25. Reversible Lymphocyte Redistribution With Fingolimod

26. Lymphopenia in Patients Treated With DMF

27. Lymphopenia in Patients Treated With Alemtuzumab or Cladribine

28. Setting Lymphocyte Count Thresholds in Clinical Practice

29. Treating to NEDA in Clinical Practice

30. Conclusions

31. Abbreviations

32. Abbreviations (cont)

33. Abbreviations (cont)